Biomarker Changes in Response to Tofacitinib Treatment in Patients With Polyarticular‐Course Juvenile Idiopathic Arthritis
Authors' conclusion
Among the CBBs included, only resistin was significantly associated with treatment response, and no CBB was identified that forecasts JIA improvement after initiation of tofacitinib.
Study context
- Population
- Patients with polyarticular-course juvenile idiopathic arthritis (JIA) treated with tofacitinib in a clinical trial143 with paired samples
- Participants
- 166 patients
- Primary endpoint
- Association of candidate blood-based biomarkers with JIA response to treatment (JADAS-27 decrease, JIA-ACR90 response)
- Follow-up
- Week 18
Methodological detailsbiomarker analysis, serial serum samples
- Biomarker analysis
- Serial serum samples
Primary result
As reported in the abstract
Association of CBBs with treatment response
- Decrease in resistin associated with week 18 improvement in Juvenile Arthritis Disease Activity Score (JADAS-27) (adjusted for age, sex, JIA disease duration, baseline resistin): r2
- 0.79
- Resistin decrease and JADAS-27 improvement: SE
- 0.070
- Resistin decrease and JADAS-27 improvement: P
- P < 0.01
- Resistin decrease and JIA-ACR90 response: OR
- 1.134 (1.018-1.264) (95% CI)
Further findings
JIA-ACR response rates · week 18
- JIA-ACR90
- 50 of 143 (35%)
- JIA-ACR70
- 90 (63%)
- JIA-ACR50
- 121 (85%)
- JIA-ACR30
- 137 (96%)
HLA-B27 positivity and not achieving JIA-ACR90 response · week 18
- HLA-B27 positivity significantly associated with not achieving JIA-ACR90
- P = 0.0097
Original publication
Biomarker Changes in Response to Tofacitinib Treatment in Patients With Polyarticular‐Course Juvenile Idiopathic Arthritis. Arthritis Care Res (Hoboken). Published 17 September 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →